Диссертация (1140950), страница 23
Текст из файла (страница 23)
Козловская Н.., Шилов Е.М., Метелева Н.А. Клинические иморфологическиеособенностиволчаночногонефритаприсистемной красной волчанке с антифосфолипидным синдромом //Терапевт.архив. 2006. (5). C. 21–31.2.КозловскаяН.Л.,ДемьяноваК.А.,КузнецовД.В.«Субклиническая» тромботическая микроангиопатия при атипичномгемолитико-уремическомсиндроме:единичныйслучайилизакономерность? // Нефрология и диализ. 2014. № 2 (16). C. 280–287.3. Лора Ш. Ф.-Б.В. Атипичный гемолитико-уремический синдром. //Нефрология. 2012. (16). C. 16–46.4.
Стрижаков Л.А. [и др.]. Клиническое значение поражениямиокарда при антифосфолипидном синдроме // Клиническаямедицина. 2006. (4). C. 56–59.5. Amara U. [и др.]. Molecular Intercommunication between theComplement and Coagulation Systems // The Journal of Immunology.2010. (185). C. 5628–5636.6. Asherson R.A. The catastrophic antiphospholipid (Asherson’s)syndrome // Autoimmun Rev.
2006. № 2 (6). C. 64–67.7. Asherson R.A., Cervera R. Microvascular and microangiopathicantiphospholipid-associatedsyndromes(’MAPS’):semanticorantisemantic? // Autoimmun Rev. 2008. № 3 (7). C. 164–167.8.AshersonR.A.,CerveraR.,GrootP.G.deCatastrophicantiphospholipid syndrome: international consensus statement onclassification criteria and treatment guidelines // Lupus. 2003. № 7 (12).C. 530–534.9. Asherson R.A., Shoenfeld Y. The role of infection in the pathogenesisof catastrophic antiphospholipid syndrome-molecular mimicry? // JRhematol. 2000.
(27). C. 12–14.13910. Asherson RA, Cervera R, Piette JCet al. Catastrophicantiphospholipid syndrome: clues to the pathogenesis from a series of 80patients. // Medicine. 2001. (80). C. 355–77.11. Bao L., Quigg R. Complement in Lupus Nephritis: The Good, theBad, and the Unknown // Semin Nephrol. 2007. № 1 (27). C. 69–80.12.
Barbour T. [и др.]. Thrombotic microangiopathy and associated renaldisorders // Nephrology Dialysis Transplantation. 2012. № 7 (27). C.2673–2685.13. Barricarte R.M., Abarrategui-garrido C., Lo M. Characterization ofcomplement factor H – related ( CFHR ) proteins in plasma reveals novelgenetic variations of CFHR1 associated with aHUS // Blood. 2009. № 19(114). C. 4261–4272.14. Besbas N, Karpman D, Landau, Daniel L.C. A classification ofhemolytic uremic syndrome and thrombotic thrombocytopenic purpuraand related disorders 2006.
(70). C. 423–431.15. Bienaime F. [и др.]. Mutations in components of complementinfluence the outcome of Factor I-associated atypical hemolytic uremicsyndrome // Kidney international. 2010. (77). C. 339–349.16. Bienaime F. [и др.]. Antiphospholipid syndrome and kidney disease// Kidney International. 2017. № 1 (91). C.
34–44.17. Breen K. [и др.]. Complement activation in patients with isolatedantiphospholipid antibodies or primary antiphospholipid syndrome //Thromb Haemost. 2012. № 3 (107). C. 423–9.18. Bresin E. [и др.]. Combined Complement Gene Mutations inAtypical Hemolytic Uremic Syndrome Influence Clinical Phenotype //Journal of the American Society of Nephrology. 2013. № 3 (24). C. 475–486.19.
Brigotti M, Carnicelli D, Ravanelli E, Barbieri S, Ricci F, BontadiniAetal.InteractionsbetweenShigatoxinsandhuman140polymorphonuclear leukocytes // J Leukoc Biol. 2008. (84(4)). C. 1019–27.20. Bu F. [и др.]. High-Throughput Genetic Testing for ThromboticMicroangiopathies and C3 Glomerulopathies // Journal of the AmericanSociety of Nephrology. 2016.
№ 4 (27). C. 1245–1253.21. Butler T. Haemolytic uraemic syndrome during shigellosis // Trans RSoc Trop Med Hyg. 2012. (106 (7)). C. 395–399.22. Campbell S., Carré I.J. Fatal haemolytic uraemic syndrome andidiopathic hyperlipaemia in monozygotic twins // Arch Dis Child. 1965.(40). C. 654–8.23. Canaud G. [и др.]. Eculizumab Improves Posttransplant ThromboticMicroangiopathy Due to Antiphospholipid Syndrome Recurrence butFails to Prevent Chronic Vascular Changes // American Journal ofTransplantation. 2013.
№ 8 (13). C. 2179–2185.24. Caprioli J. [и др.]. Complement factor H mutations and genepolymorphisms in haemolytic uraemic syndrome : the C-257T , theA2089G and the G2881T polymorphisms are strongly associated with thedisease // Human Molecular Genetics. 2003. № 24 (12). C. 3385–3395.25. Caprioli Jessica, Noris Marina , Brioschi Simona P.G. Genetics ofHUS : The impact of MCP , CFH , and IF mutations on clinicalpresentation , response to treatment , and outcome // Blood. 2006. № 4(108).
C. 1267–1279.26.CarrerasL,RomeroR,RequesensCetal.Familialhypocomplementemic hemolytic uremic syndrome with HLA-A3,B7haplotype. // JAMA. 1981. (245). C. 602–4.27. Cataland S.R. [и др.]. Biomarkers of terminal complement activationconfirm the diagnosis of aHUS and differentiate aHUS from TTP //Blood.
2014. № 24 (123). C. 3733 LP-3738.28. Cervera R. [и др.]. Antiphospholipid Syndrome Clinical and141Immunologic Manifestations and Patterns of Disease Expression in aCohort of 1,000 Patients 2002. № 4 (46). C. 1019–1027.29. Cervera R., Tincani A., Bucciarelli S. The CAPS Registry: morbidityand mortality of the catastrophic antiphospholipid syndrome // Lupus.2009. № 10 (18). C.
905–912.30. Dragon-Durey M.A., Fremeaux-bacchi V., Loirat C. Heterozygousand Homozygous Factor H Deficiencies Associated with HemolyticUremic Syndrome or Membranoproliferative Glomerulonephritis : Reportand Genetic Analysis of 16 Cases // J Am Soc Nephrol. 2004. (15). C.787–795.31. Dunnen J.T. den [и др.]. HGVS Recommendations for theDescription of Sequence Variants: 2016 Update // Human Mutation.2016. № 6 (37). C. 564–569.32. Edwards M.H. [и др.]. Hydroxychloroquine Reverses ThrombogenicProperties of Antiphospholipid Antibodies in Mice // Circulation. 1997.№ 12 (96). C.
4380 LP-4384.33. Eijgenraam J.W. The Role of Secretory IgA and Complement in IgANephropathy // Semin Nephrol. 2008. № 1 (28). C. 58–65.34. Elvington M., Liszewski M.K., Atkinson J.P. Evolution of thecomplement system: from defense of the single cell to guardian of theintravascular space // Immunological Reviews. 2016. № 1 (274). C. 9–15.35.
Eriksson K.J., Boyd S.G., Tasker R.C. Acute neurology andneurophysiology of haemolytic–uraemic syndrome // Arch Dis Child.2001. (84). C. 434–435.36. Espinosa G., Cervera R. Antiphospholipid syndrome // ArthritisResearch & Therapy. 2008. № 6 (10). C. 230.37.EspinosaG.,CerveraR.,AshersonR.A.Catastrophicantiphospholipid syndrome and sepsis. A common link? // J Rheumatol.2007.
(34). C. 923–926.14238. Fakhouri F. [и др.]. Pregnancy-associated hemolytic uremicsyndrome revisited in the era of complement gene mutations // J Am SocNephrol. 2010. (21). C. 859–867.39. Fakhouri F. [и др.]. Haemolytic uraemic syndrome // The Lancet.2017. № 17. C. 1–16.40. Fang C.J. [и др.]. Membrane cofactor protein mutations in atypicalhemolyticuremicsyndrome(aHUS),fatalStx-HUS,C3glomerulonephritis, and the HELLP syndrome // Blood.
2008. № 2 (111).C. 624–632.41. Fremeaux-bacchi V. [и др.]. Genetics and Outcome of AtypicalHemolytic Uremic Syndrome : A Nationwide French Series ComparingChildren and Adults // Clin J Am Soc Nephrol. 2013. (8). C. 554–562.42. Friedrich AW, Zhang W B.M. et al. Prevalence, Virulence Profiles,and Clinical Significance of Shiga Toxin-Negative Variants ofEnterohemorrhagic Escherichia coli O157 Infection in Humans.
//Clinical Infectious Diseases. 2007. № 1 (45). C. 39–45.43. Fujita T. Evolution of the lectin - Complement pathway and its role ininnate immunity // Nat Rev Immunol. 2002. (2). C. 346–53.44. Fujita T. Extra-immunological role of complement activation indiabetic nephropathy 2013. № 2 (1). C. 1–5.45. Galindo M., Gonzalo E., Martinez-Vidal M.P. Immunohistochemicaldetection of intravascular platelet microthrombi in patients with lupusnephritis and anti-phospholipid antibodies // Rheumatology. 2009.
№ 8(48). C. 1003–1007.46. Gasser C, Gautier E, Steck A, Siebenmann RE O.R. Hä- molytischurämische Syndrome: bilaterale Nierenrindennekrosen bei akutenerworbenen hämolytischen Anämien. // Schweiz Med Wochenschr. 1955.(85). C. 905–9.47. Geelen JM, Van der Velden T, Van den Heuvel L M.L. Interactions143of Shiga-like toxin with human peripheral blood monocytes. // PediatrNephrol. 2007. (22(8)).
C. 1181–7.48. Geerdink L.M. [и др.]. Atypical hemolytic uremic syndrome inchildren: complement mutations and clinical characteristics // PediatricNephrology. 2012. № 8 (27). C. 1283–1291.49. Girardi G. [и др.]. Complement C5a receptors and neutrophilsmediate fetal injury in the antiphospholipid syndrome // J Clin Invest.2003.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
